CDKN2A and glioblastoma: A pan-cancer survival analysis revealed that CDKN2A-ALT patients had a shorter OS and PFS than CDKN2A-WT patients in multiple cancer types, including LGG, KIRC, MESO, kidney renal papillary cell carcinoma (KIRP), pancreatic adenocarcinoma (PAAD), head and neck squamous cell carcinoma (HNSC), glioblastoma multiforme (GBM), lung adenocarcinoma (LUSC, Fig. 4F and G).